Enhertu scores ‘impressive’ new data in HER2+ breast cancer
Updated data from DESTINY-Breast01 trial continues to demonstrate efficacy
Read More
Tag: HER2-based regimen
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
- eXmoor Pharma and UCL establish strategic cell and gene therapy collaboration
- Miranda Dini launches GOLD amid industry shifts
